The article provides a useful overview of diagnosis and therapy of polycythemia rubra vera, among others. However, no mention was made of the therapeutic option of radioactive phosphorus-32. Although this nuclear medical treatment has not been administered to a great extent, it is well tolerated by patients if the indication is defined accordingly. Moreover, it is uncomplicated to administer. I am interested to find out why this therapeutic option was left out from the review article (1, 2).
References
- 1.Hautzel H. Verlagsgruppe Hüthig Jehle Rehm GmbH. 32Phosphor-Therapie der Polycythaemia vera. In: Krause BJ, Buck AK, Schwaiger M, editors. Nuklearmedizinische Onkologie. Landsberg: ecomed Medizin; 2007. pp. 587–593. [Google Scholar]
- 2.Nilsson S, Westlin J-E. Phosphorus-32 therapy in myeloproliferative disease. In: Ell PJ, Gamghir SS, editors. Nuclear medicine in clinical diagnosis and treatment. Edingburgh: Churchill Livingstone; 2004. pp. 403–405. [Google Scholar]